According to Calliditas Therapeutics's latest financial reports the company has a price-to-book ratio of 18.2.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 23.3 | 279.67% |
2022-12-31 | 6.14 | 5.64% |
2021-12-31 | 5.81 | 6.25% |
2020-12-31 | 5.47 | |
2019-12-31 | N/A | |
2018-12-31 | N/A | |
2017-12-31 | N/A |